Location of EGFR exon 20 insertions matters
Andrés Felipe Cardona1, María González-Cao2, Oscar Arrieta3
1Direction of Research, Science, and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.
Abstract:
EGFR exon 20 insertions represent a subgroup of NSCLC patients posed with a therapy dilemma. In this issue of Cancer Cell, Elamin and colleagues demonstrate that only insertions localized in the near loop respond to poziotinib. Pharmacological inhibition of spindle assembly checkpoint components inhibits tumor growth in poziotinib-resistant exon 20 insertions.
Insights
EGFR exon 20 insertions in non-small cell lung cancer (NSCLC) present a treatment challenge. Researchers found only specific near-loop insertions respond to poziotinib, while inhibiting the spindle assembly checkpoint targets resistant tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) exon 20 insertions are a distinct subtype of non-small cell lung cancer (NSCLC).
- These mutations confer resistance to standard EGFR tyrosine kinase inhibitors, creating a therapeutic dilemma.
- Identifying effective targeted therapies for this subgroup is crucial.
Purpose of the Study:
- To investigate the differential response of EGFR exon 20 insertions to poziotinib.
- To explore therapeutic strategies for poziotinib-resistant EGFR exon 20 insertion mutations.
Main Methods:
- Analysis of patient-derived cell lines and xenograft models with various EGFR exon 20 insertion mutations.
- Pharmacological treatment with poziotinib.
- Assessment of tumor growth inhibition and molecular response.
- Investigating the role of the spindle assembly checkpoint (SAC) in resistance.
Main Results:
- Poziotinib efficacy is restricted to EGFR exon 20 insertions located in the near loop region.
- Tumors with poziotinib-resistant exon 20 insertions exhibit sensitivity to pharmacological inhibition of spindle assembly checkpoint components.
- Targeting SAC components demonstrates potential for overcoming poziotinib resistance.
Conclusions:
- The localization of EGFR exon 20 insertions dictates poziotinib response.
- Spindle assembly checkpoint inhibition offers a promising therapeutic avenue for patients with resistant NSCLC harboring EGFR exon 20 insertions.
Related Concept Videos
Mitogens and the Cell Cycle
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Non-LTR Retrotransposons
The Ras Gene
Ras is a...


